Wells Fargo Downgrades Biogen (BIIB) to Equal Weight, 'Too Many Uncertainties Move Us to the Sidelines'
Tweet Send to a Friend
Wells Fargo analyst Mohit Bansal downgraded Biogen (NASDAQ: BIIB) from Overweight to Equal Weight with a price target of $240.00 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
